PODESTA GROUP, INC. for BRISTOL-MYERS SQUIBB
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Prescription Drug User Fee Act reauthorization. Diabetes drugs issues. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012. "Track and trace" issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Medical/Disease Research/Clinical Labs MED
Diabetes research issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Health Issues HCR
Diabetes issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Medicare/Medicaid MMM
Medicare coverage and reimbursement issues. Diabetes issues. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 6684, Spending Reduction Act of 2012. H.R. 8, American Taxpayer Relief Act of 2012.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.